Remove Hospitals Remove Immunity Remove Mayo Clinic
article thumbnail

Efficiency, Education, and Evolution: What’s Next for Pharmacy Practice?

Pharmacy Times

In an interview with Pharmacy Times at the 2025 Oncology Pharmacists Connect (OPC) meeting, Scott Soefje, PharmD, MBA, BCOP, director of pharmacy at Mayo Clinic, focused on the evolving role of pharmacists in healthcare, highlighting their increasing presence in outpatient settings to enhance efficiency and patient care.

article thumbnail

Nemolizumab Shows Rapid, Sustained Efficacy in Atopic Dermatitis

Pharmacy Times

Mayo Clinic. RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years. News release. June 6, 2025. Accessed June 16, 2025. Atopic Dermatitis. News release. May 15, 2024. Ferruggia K.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

This act…allowed a pathway for manufacturers to create a ‘copy’ of a licensed patent product to make it cheaper and more discounted,” Soefje, director of pharmacy cancer care services and associate professor of pharmacy at Mayo Clinic in Rochester, Minnesota, said at the HOPA conference.

article thumbnail

Immunotherapy Takes the Lead in Advanced Cutaneous Malignancies

Pharmacy Times

Have you observed these immune-related toxicities in your practice, and if so, how are they being managed? All patients should have immunotherapy first. Pharmacy Times : As immunotherapies expand into the solid tumor space, clinicians are reporting cases of ICANS and CRS. It was approved last year.

article thumbnail

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Pharmacy Times

Mayo Clinic. link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Sirtex Medical’s SIR-Spheres ® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma. News release.

article thumbnail

Pharmacists Take the Lead on Advanced Therapeutics

Pharmacy Times

These treatments are already in widespread use across health systems, from Mayo Clinic’s 9 active and 5 pending to University of California (UC) San Diego Health’s 12 active and 5 under review. At Children’s Hospital of Philadelphia (CHOP), eligible patients can access 12 advanced therapeutics and 8 more in the pipeline.

article thumbnail

Donanemab-Azbt Receives FDA Label Update With New Dosing for Alzheimer Disease

Pharmacy Times

Mayo Clinic. FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease. Eli Lilly and Company. News release. July 9, 2025. Accessed July 9, 2025. Alzheimer’s Disease. News release. November 8, 2024. Accessed July 9, 2025. link] Gallagher A. Pharmacy Times.